Center Report to the SNMMI Board of Directors  
January 2021

RADIOPHARMACEUTICAL SCIENCES COUNCIL

Council Mission: The Radiopharmaceutical Sciences Council, hereafter referred to as the Council, is a group within The Society of Nuclear Medicine and Molecular Imaging, Inc., hereafter referred to as the Society, dedicated to the interchange of scientific and medical information, ideas and knowledge among Society members who have interest in radiopharmaceutical sciences. The overall mission of the Radiopharmaceutical Sciences Council is to:

(a) provide a forum for members with similar interests  
(b) provide expertise in the field of interest to the membership  
(c) foster education in research and application of radiopharmaceutical sciences  
(d) provide outreach to other professionals, organizations and industrial partners  
(e) nurture new membership into the Society and the Council  
(f) provide recognition for professionals who have made outstanding contributions in the fields encompassed by the radiopharmaceutical sciences, and provide recognition and incentives for early stage investigators/scientists who have demonstrated their potentials in the radiopharmaceutical fields  
(g) serve as a resource to SNMMI Leadership

Council Mission and SNMMI’s Strategic Plan: The work of the Radiopharmaceutical Sciences Council, applies to the following goals and objectives in SNMMI’s Strategic Plan:

Goal B: SNMMI has advanced the development and approval of nuclear medicine and molecular imaging technologies.

Objective 1: Encourage and promote research in the field.
   a. Increase the number of facilitated collaborative research efforts among academic sites with industry.  
   b. Identify non-proprietary tracers that academic sites can help move to approval.  
   c. Reach out to experts in the field to involve them in work groups or coalitions that are producing new studies and papers.  
   d. Support and foster collaboration between academia and industry; academia looks to industry to translate initial discoveries in patient care into new technology.

Objective 2: Increase the number of initiatives targeting the discovery and validation of diagnostic radiopharmaceuticals, radiotherapeutics and instrumentation.
   a. Organize meetings/events to involve experts from the field in identifying high-impact, unmet clinical needs.  
   b. Provide essential knowledge/workshops to translate highly-demanded radiopharmaceuticals into clinical use in term of production details and regulation compliance.

Goal F: SNMMI has the organizational strength and sustainability to lead the field in a dynamic healthcare landscape.

Objective 1: Strengthen membership numbers.  
   d. Ensure enthusiasm.
iii. Create a sense of community and networking opportunities among our members.

**RPSC Council President:** Steven Liang, PhD

**RPSC Intern/Mentor:** Jessica Comstock, PharmD/Pedro Brugarolas, PhD

**Date of Last meeting:** February 3, 2021

**Date of Next meeting:** April 2021

**Update on Council Programs:**

**2021 Virtual Mid-Winter Meeting CE Sessions:**
- From First-in-Human to Reimbursement: A Practical Guide to PET Tracer Development

**2020 SNMMI Virtual Annual Meeting CE Session and Webinars:**
- Michael J. Welch Award Presentation and Lecture: Life is Like a Box of Chocolates
- Best Practices to Support the Quality Control of PET Drugs
- YIA Award Recipients: Ian Duffy, Outi Keinaenen, PhD; and Rocío García Vázquez
- BSSS

**Action Items in Progress/Pending:**
- Selection of 2021-2023 RPSC Intern
- Radiopharmacist/Radiochemist Task Force
- 2021 RPSC Awards:
  - Michael J. Welch Travel Grant: (TBD in March 2020 after abstract submission deadline)
  - Michael J. Welch Award: Victor Pike, PhD
  - Berson-Yalow Award: (TBD in March 2020 after abstract submission deadline)
  - RPSC Young Investigator Award: TBD (awarded during SNMMI AM)

**Action Items Completed:** See programs above

**Recommendations/Questions for the Board of Directors:** N/A

**Other Comments:** N/A